Association of stress induced hyperglycemia with angiographic findings and clinical outcomes in patients with ST-elevation myocardial infarction.


Journal

Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637

Informations de publication

Date de publication:
26 07 2022
Historique:
received: 02 06 2022
accepted: 21 07 2022
entrez: 26 7 2022
pubmed: 27 7 2022
medline: 29 7 2022
Statut: epublish

Résumé

Stress induced hyperglycemia (SIH) is common among patients with ST-elevation myocardial infarction (STEMI), even in patients without diabetes mellitus. However, evidence regarding its role on the angiographic outcomes and the prognosis of patients presenting with STEMI is scarce. This study included 309 consecutively enrolled STEMI patients undergoing primary percutaneous coronary intervention (pPCI). Patients were diagnosed with SIH if blood glucose on admission was > 140 mg/dl. Also, patients had to fast for at least 8 hours before blood sampling. The objective was to assess whether SIH was associated with major adverse cardiovascular and cerebrovascular (MACCE) events and explore its relationship with angiographic predictors of worse prognosis such as poor initial TIMI flow, intracoronary thrombus burden, distal embolization, and presence of residual thrombus after pPCI. SIH in diabetic and non-diabetic patients was associated with a higher incidence of LTB (aOR = 2.171, 95% CI 1.27-3.71), distal embolization (aOR = 2.71, 95% CI 1.51-4.86), and pre-procedural TIMI flow grade = 0 (aOR = 2.69, 95% CI 1.43-5.04) after adjusting for relevant clinical variables. Importantly, during a median follow-up of 1.7 years STEMI patients with SIH with or without diabetes experienced increased occurrence of MACCE both in univariate (HR = 1.92, 95% CI 1.19-3.01) and multivariate analysis (aHR = 1.802, 95% CI 1.01-3.21). SIH in STEMI patients with or without diabetes was independently associated with increased MACCE. This could be attributed to the fact that SIH was strongly correlated with poor pre-procedural TIMI flow, LTB, and distal embolization. Large clinical trials need to validate SIH as an independent predictor of adverse angiographic and clinical outcomes to provide optimal individualized care for patients with STEMI.

Sections du résumé

BACKGROUND
Stress induced hyperglycemia (SIH) is common among patients with ST-elevation myocardial infarction (STEMI), even in patients without diabetes mellitus. However, evidence regarding its role on the angiographic outcomes and the prognosis of patients presenting with STEMI is scarce.
METHODS
This study included 309 consecutively enrolled STEMI patients undergoing primary percutaneous coronary intervention (pPCI). Patients were diagnosed with SIH if blood glucose on admission was > 140 mg/dl. Also, patients had to fast for at least 8 hours before blood sampling. The objective was to assess whether SIH was associated with major adverse cardiovascular and cerebrovascular (MACCE) events and explore its relationship with angiographic predictors of worse prognosis such as poor initial TIMI flow, intracoronary thrombus burden, distal embolization, and presence of residual thrombus after pPCI.
RESULTS
SIH in diabetic and non-diabetic patients was associated with a higher incidence of LTB (aOR = 2.171, 95% CI 1.27-3.71), distal embolization (aOR = 2.71, 95% CI 1.51-4.86), and pre-procedural TIMI flow grade = 0 (aOR = 2.69, 95% CI 1.43-5.04) after adjusting for relevant clinical variables. Importantly, during a median follow-up of 1.7 years STEMI patients with SIH with or without diabetes experienced increased occurrence of MACCE both in univariate (HR = 1.92, 95% CI 1.19-3.01) and multivariate analysis (aHR = 1.802, 95% CI 1.01-3.21).
CONCLUSIONS
SIH in STEMI patients with or without diabetes was independently associated with increased MACCE. This could be attributed to the fact that SIH was strongly correlated with poor pre-procedural TIMI flow, LTB, and distal embolization. Large clinical trials need to validate SIH as an independent predictor of adverse angiographic and clinical outcomes to provide optimal individualized care for patients with STEMI.

Identifiants

pubmed: 35883091
doi: 10.1186/s12933-022-01578-6
pii: 10.1186/s12933-022-01578-6
pmc: PMC9327277
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

140

Informations de copyright

© 2022. The Author(s).

Références

Cardiovasc Diabetol. 2022 Mar 29;21(1):48
pubmed: 35351149
Eur Heart J. 2005 Apr;26(7):650-61
pubmed: 15728645
Lancet. 2000 Mar 4;355(9206):773-8
pubmed: 10711923
Am J Cardiol. 2003 Jun 19;91(12A):19H-24H
pubmed: 12818731
J Clin Med. 2020 Aug 06;9(8):
pubmed: 32781780
J Cardiol. 2016 Mar;67(3):248-53
pubmed: 26116981
J Am Coll Cardiol. 2005 Apr 5;45(7):999-1002
pubmed: 15808754
J Am Coll Cardiol. 2007 Aug 14;50(7):573-83
pubmed: 17692740
Am J Cardiol. 2020 Mar 15;125(6):851-859
pubmed: 31964502
Arch Intern Med. 2009 Mar 9;169(5):438-46
pubmed: 19273773
Diabetes Care. 2006 Apr;29(4):765-70
pubmed: 16567812
Cardiovasc Diabetol. 2018 Nov 29;17(1):152
pubmed: 30497513
Front Cardiovasc Med. 2021 Jul 20;8:698725
pubmed: 34355031
Eur Heart J. 2007 Mar;28(5):546-52
pubmed: 17314113
Exp Clin Cardiol. 2008 Fall;13(3):121-8
pubmed: 19343126
J Physiol Pharmacol. 2019 Dec;70(6):
pubmed: 32084643
Eur Heart J. 2009 Feb;30(3):305-13
pubmed: 19153179
J Thromb Thrombolysis. 2022 Jul;54(1):47-57
pubmed: 34826103
BMC Cardiovasc Disord. 2021 Feb 8;21(1):79
pubmed: 33557756
Circulation. 2018 Nov 13;138(20):e618-e651
pubmed: 30571511
J Thorac Dis. 2020 Nov;12(11):6598-6608
pubmed: 33282361
J Clin Endocrinol Metab. 2015 Dec;100(12):4490-7
pubmed: 26485219
Curr Cardiol Rev. 2012 Aug;8(3):168-76
pubmed: 22920487
JAMA. 2012 May 2;307(17):1817-26
pubmed: 22447888
Eur Heart J. 2019 Oct 1;40(37):3096
pubmed: 31292611
J Invasive Cardiol. 2010 Oct;22(10 Suppl B):6B-14B
pubmed: 20947930
Blood. 2008 Jul 1;112(1):82-9
pubmed: 18316629
Blood Coagul Fibrinolysis. 2019 Sep;30(6):270-276
pubmed: 31259777
Am J Cardiol. 2012 Mar 1;109(5):629-35
pubmed: 22152969
Diab Vasc Dis Res. 2020 Jan-Feb;17(1):1479164119883983
pubmed: 31726871
Circulation. 2008 Mar 25;117(12):1610-9
pubmed: 18299505
Neth Heart J. 2018 Sep;26(9):417-421
pubmed: 29974355
Front Cardiovasc Med. 2021 May 12;8:676892
pubmed: 34055942
Front Med (Lausanne). 2019 Mar 27;6:54
pubmed: 30972338

Auteurs

Nikolaos Stalikas (N)

First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636, Thessaloniki, Greece.

Andreas S Papazoglou (AS)

First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636, Thessaloniki, Greece.

Efstratios Karagiannidis (E)

First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636, Thessaloniki, Greece.

Eleftherios Panteris (E)

Laboratory of Forensic Medicine and Toxicology, School of Medicine, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece.
Biomic_Auth, Bioanalysis and Omics Lab, Centre for Interdisciplinary Research of Aristotle University of Thessaloniki, Innovation Area of Thessaloniki, 57001, Thermi, Greece.

Dimitrios Moysidis (D)

First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636, Thessaloniki, Greece.

Stylianos Daios (S)

First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636, Thessaloniki, Greece.

Vasileios Anastasiou (V)

First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636, Thessaloniki, Greece.

Vasiliki Patsiou (V)

First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636, Thessaloniki, Greece.

Triantafyllia Koletsa (T)

Pathology Department, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

George Sofidis (G)

First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636, Thessaloniki, Greece.

Georgios Sianos (G)

First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636, Thessaloniki, Greece.

George Giannakoulas (G)

First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636, Thessaloniki, Greece. ggiannakoulas@auth.gr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH